Login to Your Account



MacroGenics Looks to Pipeline After Teplizumab Phase III Miss

By Trista Morrison


Friday, October 22, 2010
MacroGenics Inc. and partner Eli Lilly and Co.'s teplizumab failed to meet its primary efficacy endpoint in a Phase III trial for Type 1 diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription